跳至主要内容
临床试验/NCT04002362
NCT04002362已完成2 期

Symptom Clusters in Children With Exacerbation-prone Asthma

Emory University2 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2019年11月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
68
试验地点
2
主要终点
Change in Asthma Control Questionnaire (ACQ) Score

研究概览

简要总结

Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the temporal stability of the symptom clusters.

详细描述

Asthma symptom control is suboptimal in the majority of children in the United States, despite widespread availability of asthma controller medications and standardized treatment guidelines. While deaths from asthma have declined, 53.7% of children with asthma continue to experience an exacerbation each year and the associated public health burden is substantial.

While the factors responsible for poor asthma symptom control are complex and include limited access to care, poor adherence to preventative asthma medications, and exposures to environmental allergens and irritants such as tobacco smoke, it is also recognized that children with exacerbation-prone asthma are a heterogeneous group with differing clinical outcomes and longitudinal disease trajectories. Symptoms (defined as subjective sensations) can also be quite varied within and among affected children. Whereas some children have persistent, troublesome respiratory symptoms, others have respiratory symptoms only with upper respiratory infections. Mental health symptoms and social health symptoms have been inadequately characterized in this population, but some children with asthma also report depression and anxiety and impaired family functioning and relationships that may further worsen asthma outcomes. However, prior studies are limited by a narrow focus on individual symptoms in isolation. To date, there has been no attempt to identify symptom clusters (defined as two or more concurrent symptoms independent of other clusters) in children with exacerbation-prone asthma.

Poor understanding of symptom clusters is a major shortcoming in asthma symptom science. In other chronic disorders such as cancer, compared with a single symptom, symptom clusters of pain, fatigue, sleep disturbance and mood disturbance significantly worsen patient-reported outcomes of functional status and quality of life. There is also emerging evidence that interventions for one symptom within a cluster (i.e., cognitive-behavioral therapy for pain) reduce the severity of other symptoms within that cluster (i.e., fatigue and sleep disturbance). Because children with exacerbation-prone asthma rarely report a single symptom, greater knowledge of the assessment (and ultimately management) of symptom clusters in these children has the potential to significantly improve individualized treatment and clinical outcomes.

The researchers propose a 48-week cohort study to test the overarching hypothesis that symptom clusters and their associated inflammatory and metabolic pathways predict corticosteroid treatment responsiveness (primary objective outcome) and quality of life (patient-reported secondary outcome) in children 6- 21years of age with exacerbation-prone asthma. Participants will be given the option to either: 1) complete a single study visit, with telephone/email contacts and a review of their electronic medical record for up to 48 weeks after enrollment, or 2) complete the 48-week cohort study with scheduled study visits. Participants who select option 2 with follow-up over 48 weeks will also have the option to complete visits 3, 4 and 5 by telephone.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Age 6 to less than 21 years at the enrollment visit
  • Physician diagnosis of asthma
  • History of an asthma exacerbation in the previous 12 months, defined as either:
  • Treatment with systemic corticosteroids, or
  • Increase in rescue medication use (i.e., albuterol or inhaled corticosteroid) for 24 hours or more, or
  • One or more missed school days due to asthma symptoms, or
  • An unscheduled visit for asthma at either a physician's office, urgent care, hospital emergency room, or
  • Hospitalization for asthma

排除标准

  • Previous allergic reaction to systemic corticosteroids
  • Hepatic, biliary, or renal disease that can interfere with drug metabolism/excretion
  • Chronic medical disorders that may increase the risk of drug-related injury, including osteogenesis imperfecta (increased risk of fracture with corticosteroids), or Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting disorders, or Factor deficiency (increased risk of bleeding with corticosteroid therapy)
  • Pregnancy
  • Current smoking
  • Congenital disorders or deformities of the chest wall, lungs or airways
  • History of premature birth <35 weeks gestation
  • Unwillingness to receive triamcinolone
  • Planning to relocate before study completion

研究组 & 干预措施

Triamcinolone Acetonide

Experimental

Pediatric participants with exacerbation-prone asthma receiving an intramuscular injection of triamcinolone acetonide and are followed for 48 weeks.

干预措施: Triamcinolone Acetonide (Drug)

结局指标

主要结局

Change in Asthma Control Questionnaire (ACQ) Score

时间窗: Baseline, Day 14

Responsiveness to the study treatment is assessed with the ACQ. This 7-item questionnaire includes questions related to daytime and nocturnal symptoms, short-acting bronchodilator use, and lung function during the clinic visit on that day. Participants report how difficult their asthma was to control on a scale from 0 (no impairment) to 6 (maximum impairment). Total raw scores range from 0 to 42, with higher scores indicating poorer asthma control. Responsiveness to treatment is determined with the mean difference in ACQ score the baseline visit and the Day 14 visit, with a reduction of 0.5 considered a minimally important difference.

次要结局

  • Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Asthma Impact Scale (PAIS)(Weeks 16, 32, and 48)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne M Fitzpatrick

Professor

Emory University

研究点 (2)

Loading locations...

相似试验